Sucralfate — $0 with Membership
Sucralfate has an active canonical formulary match. No-additional-cost pricing is subject to its listed supply, quantity, fill, and fulfillment limits.
Sucralfate Pricing
| Pricing type | Price |
|---|---|
| TheDrugClub | $0 with membership |
| Typical Retail | $89.99 |
Free with membership subject to the listed formulary limits.
About Sucralfate
Sucralfate is a prescription medication. Ask your doctor if Sucralfate is right for you.
Conditions Treated with Sucralfate
How to Check Sucralfate Pricing
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available membership pricing
Sucralfate at Participating Pharmacies
- CVS Pharmacy
- Walgreens
- Walmart Pharmacy
- Rite Aid
- Kroger Pharmacy
- Costco Pharmacy
- Albertsons
- Safeway
- Publix Pharmacy
- H-E-B Pharmacy
Pharmacy participation and fulfillment options vary. Present your membership card and confirm current pricing before filling.
Related medications
Other medications associated with the same conditions in this catalog.
Also listed for Peptic Ulcer Disease
Other medications in Gastrointestinal
About Sucralfate
Sucralfate is a unique medication often prescribed to treat and prevent ulcers in the stomach and intestines, as well as manage conditions like GERD. It works by forming a protective barrier, allowing your digestive lining to heal. At TheDrugClub, we believe essential medications like sucralfate should be accessible and affordable, helping our members save significantly.
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.
What Sucralfate is approved for (FDA label)
Sucralfate is indicated in: • Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. • Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers.
Source: Read the full FDA label on DailyMed. Label effective date: September 2, 2026.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Adverse reactions for Sucralfate (FDA label)
Adverse reactions to sucralfate in clinical trials were minor and only rarely led to discontinuation of the drug. In studies involving over 2,700 patients treated with sucralfate tablets, adverse effects were reported in 129 (4.7%). Constipation was the most frequent complaint (2%). Other adverse effects reported in less than 0.5% of the patients are listed below by body system: Gastrointestinal: diarrhea, nausea, vomiting, gastric discomfort, indigestion, flatulence, dry mouth Dermatological: pruritus, rash Nervous System: dizziness, insomnia, sleepiness, vertigo Other: back pain, headache Post-marketing: cases of hypersensitivity have been reported with the use of sucralfate tablets, including dyspnea, lip swelling, pruritus, rash, and urticaria.
Source: FDA prescribing information (DailyMed). Set ID: 536b8c00-13ab-4397-a754-63a1c92bf883. SPL document ID: c188e20b-1bd3-40e7-996b-7291464b1301. Label effective date: September 2, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Contraindications for Sucralfate (FDA label)
Sucralfate is contraindicated in patients with known hypersensitivity reactions to the active substance or to any of the excipients.
Source: FDA prescribing information (DailyMed). Set ID: 536b8c00-13ab-4397-a754-63a1c92bf883. SPL document ID: c188e20b-1bd3-40e7-996b-7291464b1301. Label effective date: September 2, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.
Drug interactions for Sucralfate (FDA label)
Some studies have shown that simultaneous sucralfate administration in healthy volunteers reduced the extent of absorption (bioavailability) of single doses of the following: cimetidine, digoxin, fluoroquinolone antibiotics, ketoconazole, l-thyroxine, phenytoin, quinidine, ranitidine, tetracycline, and theophylline. Subtherapeutic prothrombin times with concomitant warfarin and sucralfate therapy have been reported in spontaneous and published case reports. However, two clinical studies have demonstrated no change in either serum warfarin concentration or prothrombin time with the addition of sucralfate to chronic warfarin therapy. The mechanism of these interactions appears to be nonsystemic in nature, presumably resulting from sucralfate binding to the concomitant agent in the gastrointestinal tract. In all case studies to date (cimetidine, ciprofloxacin, digoxin, norfloxacin, ofloxacin, and ranitidine), dosing the concomitant medication 2 hours before sucralfate eliminated the interaction.
Source: FDA prescribing information (DailyMed). Set ID: 536b8c00-13ab-4397-a754-63a1c92bf883. SPL document ID: c188e20b-1bd3-40e7-996b-7291464b1301. Label effective date: September 2, 2026. Read the full label.
Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.